Cervical Squamous Cell Carcinoma Clinical Trial
Official title:
Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study
NCT number | NCT01759355 |
Other study ID # | LCCC1221 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2012 |
Est. completion date | May 28, 2020 |
Verified date | December 2021 |
Source | UNC Lineberger Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a two arm, single center feasibility study of 20 patients with non-metastatic cervical cancer managed with surgery and/or chemoradiation therapy at UNC Hospitals. Subjects will undergo PET/MRI scans before, during (chemoradiation group only), and after treatment.
Status | Completed |
Enrollment | 18 |
Est. completion date | May 28, 2020 |
Est. primary completion date | May 28, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18 years of age - Biopsy-proven, previously untreated squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the uterine cervix - Clinically visible lesion at least FIGO stage Ib or AJCC 7th edition T1b - Scheduled to undergo standard of care PET/CT for baseline assessment of disease - Anticipated to be eligible for curative intent therapy (surgery of chemoradiation therapy) as determined by the patient's primary oncologist - If female of child-bearing potential, negative serum or urine pregnancy test = 7 dats prior to first PET/MRI - Informed consent reviewed and signed Exclusion Criteria: - History of sever reaction to contrast-enhanced CT scan - Inability to tolerate MRI (e.g., inability to lie flat > 1 hour) - Presence of pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes - Poorly controlled diabetes mellitus - Creatinine > 1.4 mg/dL or GFR < 30 mL/min - Body Mass Index (BMI) > 35 - Active vaginal bleeding requiring packing and emergent radiation therapy - Pregnant or lactating female - History of a prior malignancy within past 5 years, unless disease free for = 3 years - Substance abuse, medical, psychological, or social conditions that may interfere with study participation |
Country | Name | City | State |
---|---|---|---|
United States | University of North Carolina-Chapel Hill | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
UNC Lineberger Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients who successfully complete PET/MR scans at all study time-points | 2-3 months post-treatment | ||
Secondary | Sensitivity of PET/MR for baseline disease assessment | Estimated proportion of subjects with disease (positive pathology or PET/CT) that have positive PET/MR scans. | pre-treatment | |
Secondary | Specificity of hybrid PET/MR for baseline disease assessment | Proportion of subjects without disease (negative pathology or PET/CT) that have negative PET/MR scans. | pre-treatment | |
Secondary | Accuracy of hybrid PET/MR for baseline disease assessment | Proportion of correct assessments among total population | pre-treatment | |
Secondary | Detection of disease with PET/MR at each time point | pre-treatment to 2-3 months post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05013268 -
Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma
|
Phase 1 | |
Completed |
NCT02562729 -
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer
|
Phase 2 | |
Completed |
NCT00054444 -
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
|
Phase 1 | |
Completed |
NCT00416455 -
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Completed |
NCT00068549 -
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03983954 -
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00559377 -
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
|
Phase 2 | |
Completed |
NCT00309959 -
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05613283 -
Primary Cervical Cancer Screening by Self-sampling HPV Test
|
||
Completed |
NCT00064077 -
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
|
Phase 3 | |
Active, not recruiting |
NCT02466971 -
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
|
Phase 3 | |
Completed |
NCT02164461 -
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
|
Phase 1 | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00031993 -
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
|
Phase 2 | |
Active, not recruiting |
NCT01649089 -
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
|
N/A | |
Completed |
NCT00499031 -
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Terminated |
NCT00070317 -
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
|
N/A | |
Not yet recruiting |
NCT04976478 -
Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
|
||
Active, not recruiting |
NCT03738228 -
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
|
Phase 1 |